SCHEMBL476802

SCHEMBL476802

C[C@H](OC(=O)N[C@H]1CCNC1)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.36
HDAC4 P56524 2/20 0.36
KCNH2 Q12809 1/20 0.34
SSTR1 P30872 2/20 0.33
SSTR4 P31391 2/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
OPRK1 P41145 1/20 0.33
HDAC6 Q9UBN7 1/20 0.32
DRD4 P21917 1/20 0.32
PARP1 P09874 1/20 0.32
KDM1A O60341 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SCN9A Q15858 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476829 1.00 EPHX1 (0.36) EPHX1HDAC4KCNH2SSTR1SSTR4
SCHEMBL10060054 0.83 EPHX1 (0.41) EPHX1KCNH2POLBMAPK1OPRK1
SCHEMBL14486852 0.83 EPHX1 (0.41) EPHX1KCNH2POLBMAPK1OPRK1
Hydrochloric Acid SCHEMBL17560375 0.81 EPHX1 (0.40) EPHX1KCNH2POLBMAPK1OPRK1
Hydrochloric Acid SCHEMBL17560372 0.81 EPHX1 (0.40) EPHX1KCNH2POLBMAPK1OPRK1
SCHEMBL1778461 0.76 EPHX1 (0.47) EPHX1KCNH2POLBMAPK1OPRK1
SCHEMBL14222420 0.76 EPHX1 (0.47) EPHX1KCNH2POLBMAPK1OPRK1
SCHEMBL5320954 0.76 EPHX1 (0.47) EPHX1KCNH2POLBMAPK1OPRK1
SCHEMBL584883 0.74 KCNH2 (0.39) EPHX1HDAC4KCNH2POLBMAPK1
Hydrochloric Acid SCHEMBL17560408 0.74 EPHX1 (0.45) EPHX1KCNH2POLBMAPK1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492397-B2 Aminopyridine derivatives having Aurora A selective inhibitory action VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-23 US disclosed
US-20120029004-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICALS CO., LTD. (JP) 2012-02-02 US disclosed
EP-2411010-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION MSD K.K. (JP) 2012-02-01 EP disclosed
WO-2010111050-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029004-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION AURKA, AURKC, AURKB EPHX1 3629/4885HDAC4 665/4885KCNH2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.